Jiraskova, L.; Ryska, A.; Duintjer Tebbens, E.J.; Hornychova, H.; Cecka, F.; Staud, F.; Cerveny, L.
Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy? Cancers 2019, 11, 1621.
https://doi.org/10.3390/cancers11111621
AMA Style
Jiraskova L, Ryska A, Duintjer Tebbens EJ, Hornychova H, Cecka F, Staud F, Cerveny L.
Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy? Cancers. 2019; 11(11):1621.
https://doi.org/10.3390/cancers11111621
Chicago/Turabian Style
Jiraskova, Lucie, Ales Ryska, Erik Jurjen Duintjer Tebbens, Helena Hornychova, Filip Cecka, Frantisek Staud, and Lukas Cerveny.
2019. "Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy?" Cancers 11, no. 11: 1621.
https://doi.org/10.3390/cancers11111621
APA Style
Jiraskova, L., Ryska, A., Duintjer Tebbens, E. J., Hornychova, H., Cecka, F., Staud, F., & Cerveny, L.
(2019). Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy? Cancers, 11(11), 1621.
https://doi.org/10.3390/cancers11111621